진균성 각막염 치료 시장 : 치료 유형별, 적응증별, 진균종별, 연령대별, 최종사용자별 - 세계 전망

Global Fungal Keratitis Treatment Market will grow at 6.1% CAGR during 2024-2032 due to the increasing prevalence of Keratitis Fungal globally. According to EyeWiki, fungal keratitis is a growing global phenomenon with increasing prevalence worldwide. The increase in cases is due to several factors, including improper contact lens hygiene, eye injuries, and agricultural practices. As the prevalence of corneal fungal infections continues to rise, the need for rapid diagnosis and effective treatment measures increases. The growing number of cases increases the demand for innovative treatment solutions and promotes the research and development needed to address this clinical challenge.

A visible trend is an increasing focus on combination therapy. Recognizing the challenges presented by fungal resistance to conventional antifungal drugs, researchers and clinicians are exploring synergistic combinations of antifungal agents to improve efficacy and minimize the risk of developing resistance. By combining several treatments, such as antifungal eye drops, systemic medications, and adjuvant therapy, such as corneal collagen cross-linking, doctors try to improve treatment results and speed up the healing of fungal keratitis.

The overall Fungal Keratitis Treatment industry is classified based on treatment type, indication, fungal species, age group, end user, and region.

The deep keratitis segment will grow rapidly through 2032, as deep keratitis, characterized by fungal penetration into the deeper layers of the cornea, carries an increased risk of vision loss and corneal perforation if left untreated. As such, effective treatment of deep keratitis requires aggressive antifungal therapy, often combined with surgical procedures such as corneal transplantation or therapeutic keratoplasty. With advances in surgical techniques and the development of targeted antifungal agents, the prognosis of patients with deep keratitis has improved significantly, increasing the demand for comprehensive treatment regimens tailored to the severity and depth of corneal involvement.

The adult segment will grow decently through 2032 as occupational exposure, use of contact lenses, and weakened immune systems increase the susceptibility of adults to fungal keratitis. In addition, lifestyle factors such as outdoor activities and agricultural work increase the risk of eye injuries and exposure to fungal diseases. As such, adults represent a significant proportion of patients seeking treatment for fungal keratitis, increasing the demand for effective therapeutic interventions tailored to their unique clinical needs and risk profiles.

Europe Fungal Keratitis Treatment industry will grow significantly through 2032, characterized by the convergence of clinical knowledge, research innovation, and regulatory oversight. Europe has a strong healthcare infrastructure and ophthalmic research ecosystem that fosters collaboration between academic institutions, healthcare providers, and pharmaceutical companies to develop therapies for fungal keratitis. Countries such as the United Kingdom, Germany, and France are at the forefront of clinical research and therapeutic innovation in the field of ophthalmology, which is driving market growth and the adoption of new treatments. In addition, strict regulatory standards and reimbursement practices ensure that patients have access to quality care and innovative treatments.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing incidence of eye infections
    • 3.2.1.2 Growing geriatric population
    • 3.2.1.3 Increasing prevalence of contact lens wear
    • 3.2.1.4 Increasing research and development activities
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects associated with the antifungal medications
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Million)

• 5.1 Key trends
• 5.2 Medical treatment
  • 5.2.1 Drug class
    • 5.2.1.1 Polyenes
      • 5.2.1.1.1 Natamycin
      • 5.2.1.1.2 Amphotericin B
    • 5.2.1.2 Azoles
      • 5.2.1.2.1 Triazole
      • 5.2.1.2.1.1 Voriconazole
      • 5.2.1.2.1.2 Fluconazole
      • 5.2.1.2.1.3 Itraconazole
      • 5.2.1.2.1.4 Posaconazole
      • 5.2.1.2.2 Imidazoles
      • 5.2.1.2.2.1 Econazole
      • 5.2.1.2.2.2 Miconazole
      • 5.2.1.2.2.3 Ketoconazole
    • 5.2.1.3 Other drug classes
  • 5.2.2 Route of administration
    • 5.2.2.1 Topical
    • 5.2.2.2 Oral
    • 5.2.2.3 Injectable
• 5.3 Surgical treatment

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Million)

• 6.1 Key trends
• 6.2 Superficial keratitis
• 6.3 Deep keratitis

Chapter 7 Market Estimates and Forecast, By Fungal Species, 2021 - 2032 ($ Million)

• 7.1 Key trends
• 7.2 Fusarium
• 7.3 Aspergillus
• 7.4 Candida
• 7.5 Cephalosporium
• 7.6 Other species

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Million)

• 8.1 Key trends
• 8.2 Children
• 8.3 Adults
• 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Million)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Clinics
• 9.4 ASCs
• 9.5 Other end-users

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Alvogen
• 11.2 Aurolab
• 11.3 Bausch Health Companies Inc.
• 11.4 Eyevance Pharmaceuticals LLC
• 11.5 Gilead Biosciences, Inc.
• 11.6 Glenmark Pharmaceuticals Ltd.
• 11.7 Leadiant Biosciences, Inc.
• 11.8 Merck & Co. Inc.
• 11.9 Novo Holdings A/S (Xellia Pharmaceuticals)
• 11.10 Pfizer Inc.